U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry RACEMIC
Molecular Formula C6H11NO2
Molecular Weight 129.157
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Vigabatrin

SMILES

NC(CCC(O)=O)C=C

InChI

InChIKey=PJDFLNIOAUIZSL-UHFFFAOYSA-N
InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020427s010s011s012,022006s011s012s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/22061175

Vigabatrin is an anticonvulsant chemically unrelated to other anticonvulsants. Vigabatrin prevents the catabolism of GABA by irreversibly inhibiting the enzyme GABA transaminase. It is an analog of GABA, but it is not a receptor agonist. However, vigabatrin is not a potent inhibitor of GABA-T with a Ki of 10 mM. Vigabatrin increases brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by irreversibly inhibiting enzymes that catabolize GABA (gamma-aminobutyric acid transaminase, GABA-T). Duration of action is determined by rate of GABA-T re-synthesis. Vigabatrin may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. Although administered as a racemic mixture, only the S(+) enantiomer is pharmacologically active. Vigabatrin is sold under the trade name SABRIL, it is indicated as adjunctive therapy for adults and pediatric patients 10 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
SABRIL

Approved Use

SABRIL is an antiepileptic drug (AED) indicated for: • Refractory Complex Partial Seizures in Adults (1.1). It should be used as adjunctive therapy in patients who have responded inadequately to several alternative treatments.

Launch Date

2009
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
18.4 μg/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
VIGABATRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
73 μg × h/mL
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
VIGABATRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7 h
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
VIGABATRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
2 g single, oral
dose: 2 g
route of administration: Oral
experiment type: SINGLE
co-administered:
VIGABATRIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Disc. AE: Sedation, Seizures...
Other AEs: Weight gain, Depression...
AEs leading to
discontinuation/dose reduction:
Sedation (9%)
Seizures (2%)
Status epilepticus (1%)
Other AEs:
Weight gain (6%)
Depression (1%)
Excitability (1%)
Itching (1%)
Headache (1%)
Irritability (1%)
Muscle pain (1%)
Libido decreased (1%)
Sources:
2 g 2 times / day multiple, oral
Highest studied dose
Dose: 2 g, 2 times / day
Route: oral
Route: multiple
Dose: 2 g, 2 times / day
Sources:
healthy, 25.8 ± 8.2
Health Status: healthy
Age Group: 25.8 ± 8.2
Sex: M
Sources:
4 g single, oral
Highest studied dose
Dose: 4 g
Route: oral
Route: single
Dose: 4 g
Sources:
healthy, 27.0 ± 8.2
Health Status: healthy
Age Group: 27.0 ± 8.2
Sex: M
Sources:
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
unhealthy, 35 ± 11
Health Status: unhealthy
Age Group: 35 ± 11
Sex: M+F
Sources:
90 g single, oral
Overdose
unhealthy
Other AEs: Coma, Unconsciousness...
Other AEs:
Coma (common)
Unconsciousness (common)
Drowsiness (common)
Vertigo (uncommon)
Psychosis (uncommon)
Apnea (uncommon)
Respiratory depression (uncommon)
Bradycardia (uncommon)
Agitation (uncommon)
Irritability (uncommon)
Confusion (uncommon)
Headache (uncommon)
Hypotension (uncommon)
Abnormal behavior (uncommon)
Seizures (uncommon)
Status epilepticus (uncommon)
Speech disorder (uncommon)
Sources:
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources:
unhealthy
Other AEs: Vision loss, Brain MRI signal changes...
Other AEs:
Vision loss
Brain MRI signal changes
Suicidal behavior
Suicidal ideation
Anemia
Somnolence
Fatigue
Sources:
AEs

AEs

AESignificanceDosePopulation
Depression 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Excitability 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Headache 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Irritability 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Itching 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Libido decreased 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Muscle pain 1%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Status epilepticus 1%
Disc. AE
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Seizures 2%
Disc. AE
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Weight gain 6%
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Sedation 9%
Disc. AE
2 g 1 times / day multiple, oral
Highest studied dose
Dose: 2 g, 1 times / day
Route: oral
Route: multiple
Dose: 2 g, 1 times / day
Sources:
unhealthy, 16-63
Health Status: unhealthy
Age Group: 16-63
Sex: M+F
Sources:
Coma common
90 g single, oral
Overdose
unhealthy
Drowsiness common
90 g single, oral
Overdose
unhealthy
Unconsciousness common
90 g single, oral
Overdose
unhealthy
Abnormal behavior uncommon
90 g single, oral
Overdose
unhealthy
Agitation uncommon
90 g single, oral
Overdose
unhealthy
Apnea uncommon
90 g single, oral
Overdose
unhealthy
Bradycardia uncommon
90 g single, oral
Overdose
unhealthy
Confusion uncommon
90 g single, oral
Overdose
unhealthy
Headache uncommon
90 g single, oral
Overdose
unhealthy
Hypotension uncommon
90 g single, oral
Overdose
unhealthy
Irritability uncommon
90 g single, oral
Overdose
unhealthy
Psychosis uncommon
90 g single, oral
Overdose
unhealthy
Respiratory depression uncommon
90 g single, oral
Overdose
unhealthy
Seizures uncommon
90 g single, oral
Overdose
unhealthy
Speech disorder uncommon
90 g single, oral
Overdose
unhealthy
Status epilepticus uncommon
90 g single, oral
Overdose
unhealthy
Vertigo uncommon
90 g single, oral
Overdose
unhealthy
Anemia
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources:
unhealthy
Brain MRI signal changes
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources:
unhealthy
Fatigue
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources:
unhealthy
Somnolence
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources:
unhealthy
Suicidal behavior
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources:
unhealthy
Suicidal ideation
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources:
unhealthy
Vision loss
1500 mg 2 times / day multiple, oral
Recommended
Dose: 1500 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 2 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
weak (co-administration study)
Comment: A 16% to 20% average reduction in total phenytoin plasma levels was reported (see label page 21)
Page: 70.0
likely
weak (co-administration study)
Comment: A 16% to 20% average reduction in total phenytoin plasma levels was reported (see label page 21)
Page: 70.0
no
no (co-administration study)
Comment: No significant difference in pharmacokinetic parameters of vigabatrin were found after treatment with ethinyl estradiol and levonorgestrel; vigabatrin did not interfere significantly with the cytochrome P450 isoenzyme (CYP3A)-mediated metabolism of the contraceptive tested
Page: 22.0
no
no (co-administration study)
Comment: No significant difference in pharmacokinetic parameters of vigabatrin were found after treatment with ethinyl estradiol and levonorgestrel; vigabatrin did not interfere significantly with the cytochrome P450 isoenzyme (CYP3A)-mediated metabolism of the contraceptive tested
Page: 22.0
not significant
not significant
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
GABA changes with vigabatrin in the developing human brain.
1999 Apr
Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings.
1999 Dec 10
Elimination of oxcarbazepine-induced oculogyric crisis following vagus nerve stimulation.
1999 Jun 10
Preclinical evaluation of newly approved and potential antiepileptic drugs against cocaine-induced seizures.
1999 Sep
[Visual field changes secondary to vigabatrin treatment].
2000 Dec 16-31
Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine.
2000 Feb
Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: is young age a favorable factor?
2000 Jun
Vigabatrin-associated visual field defects in children.
2000 Jun
Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.
2000 Nov
Visual field defects in patients taking vigabatrin.
2000 Oct
Anti-spasticity agents for multiple sclerosis.
2001
GABAergic mechanisms in epilepsy.
2001
The new generation of GABA enhancers. Potential in the treatment of epilepsy.
2001
Visual field defects with vigabatrin: epidemiology and therapeutic implications.
2001
Behavioural effects of the new anticonvulsants.
2001
New developments in the pharmacotherapy of alcohol dependence.
2001
Update on anticonvulsants for the treatment of alcohol withdrawal.
2001
Visual function is stable in patients who continue long-term vigabatrin therapy: implications for clinical decision making.
2001 Apr
Newer antiepileptic drugs: advantages and disadvantages.
2001 Aug
Paradoxical reduction of synaptic inhibition by vigabatrin.
2001 Aug
Infantile spasms.
2001 Feb
Increased vigabatrin entry into the brain by polysorbate 80 and sodium caprate.
2001 Feb
The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat.
2001 Feb
Determination of the antiepileptics vigabatrin and gabapentin in dosage forms and biological fluids using Hantzsch reaction.
2001 Feb
Nicotine-conditioned locomotor activity in rats: dopaminergic and GABAergic influences on conditioned expression.
2001 Jan
The use of vigabatrin in infantile spasms in Asian children.
2001 Jan
[Evaluation of extensive visual field defects with computer-assisted kinetic perimetry].
2001 Jan
Effects of vigabatrin on brain GABA+/CR signals in patients with epilepsy monitored by 1H-NMR-spectroscopy: responder characteristics.
2001 Jan
Revised guideline for prescribing vigabatrin in children. Guideline's claim about infantile spasms is not based on appropriate evidence.
2001 Jan 27
Changes in color vision after a single dose of vigabatrin or carbamazepine in healthy volunteers.
2001 Jan-Feb
Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: How valid is the GABAergic hypothesis?
2001 Jul
Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina.
2001 Jul 24
Placental transfer of vigabatrin (gamma-vinyl GABA) and its effect on concentration of amino acids in the embryo of TO mice.
2001 Mar
Chronic elevation of brain GABA levels beginning two days after status epilepticus does not prevent epileptogenesis in rats.
2001 Mar
Development of a stable-isotope dilution assay for gamma-aminobutyric acid (GABA) transaminase in isolated leukocytes and evidence that GABA and beta-alanine transaminases are identical.
2001 Mar
[Social and economic aspects of administration of new antiepileptic drugs].
2001 Mar-Apr
Vigabatrin visual toxicity: evolution and dose dependence.
2001 May
West syndrome and other infantile epileptic encephalopathies--Indian hospital experience.
2001 Nov
West syndrome: a university hospital based study from Oman.
2001 Nov
Gamma vinyl-GABA differentially modulates NMDA antagonist-induced increases in mesocortical versus mesolimbic DA transmission.
2001 Nov
Anxiolytic effects of vigabatrin in panic disorder.
2001 Oct
Plasticity of rat central inhibitory synapses through GABA metabolism.
2001 Sep 1
Determination of vigabatrin in human plasma and urine by high-performance liquid chromatography with fluorescence detection.
2001 Sep 5
Patents

Patents

Sample Use Guides

Refractory Complex Partial Seizures Adults >16 years of age: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1500 mg twice daily (2.2). Pediatrics 10 to 16 years of age: Treatment is based on body weight. Initiate therapy at 250 mg twice daily, increasing total daily dose per instructions. The recommended maintenance dose is 1000 mg twice daily. Patients weighing more than 60 kg should be dosed according to adult recommendations (2.2). Infantile Spasms Initiate therapy at 50 mg/kg/day given in 2 divided doses increasing total daily dose per instructions to a maximum of 150 mg/kg/day given in 2 divided doses (2.3). Given orally with or without food.
Route of Administration: Oral
Vigabatrin inhibits the uptake of taurine in Caco-2 and MDCK cells to 34 ± 3 and 53 ± 2%, respectively, at a concentration of 30 mM.
Name Type Language
Vigabatrin
DASH   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
SABRIL
Preferred Name English
Vigabatrin [WHO-DD]
Common Name English
4-Amino-5-hexenoic acid
Systematic Name English
GAMMA-VINYL GABA
Common Name English
Vigabatrin [INN]
Common Name English
Vigabatrin [USP MONOGRAPH]
Common Name English
VINYL GAMMA-AMINOBUTYRIC ACID
Systematic Name English
Vigabatrin [USAN]
Common Name English
Vigabatrin [ORANGE BOOK]
Common Name English
Vigabatrin, (±)-
Common Name English
Vigabatrin [MART.]
Common Name English
Vigabatrin [EP MONOGRAPH]
Common Name English
Vigabatrin [JAN]
Common Name English
5-Hexenoic acid, 4-amino-
Systematic Name English
MDL 71,754
Code English
RMI-71754
Code English
CPP-109
Code English
GAMMA VINYL GABA
Common Name English
VIGABATRIN [USP-RS]
Common Name English
MDL-71754
Code English
VIGAFYDE
Brand Name English
Vigabatrin [VANDF]
Common Name English
Vigabatrin [MI]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 609817
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
NCI_THESAURUS C264
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
FDA ORPHAN DRUG 135100
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
WHO-ATC N03AG04
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
LIVERTOX NBK548253
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
NDF-RT N0000175753
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
FDA ORPHAN DRUG 905322
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
WHO-VATC QN03AG04
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
Code System Code Type Description
PUBCHEM
5665
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
RS_ITEM_NUM
1712001
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
RXCUI
14851
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY RxNorm
DRUG BANK
DB01080
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
MESH
D020888
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
LACTMED
Vigabatrin
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
WIKIPEDIA
VIGABATRIN
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
FDA UNII
GR120KRT6K
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
NCI_THESAURUS
C87611
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
EVMPD
SUB00048MIG
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
CAS
60643-86-9
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
SUPERSEDED
INN
5581
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
IUPHAR
4821
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
DRUG CENTRAL
2819
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
DAILYMED
GR120KRT6K
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
SMS_ID
100000079084
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
USAN
U-75
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
MERCK INDEX
m11445
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY Merck Index
CAS
68506-86-5
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
ChEMBL
CHEMBL89598
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
CHEBI
63638
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY
EPA CompTox
DTXSID4041153
Created by admin on Mon Mar 31 18:38:39 GMT 2025 , Edited by admin on Mon Mar 31 18:38:39 GMT 2025
PRIMARY